Breast Cancer · 2024 · 14 citations · 29 references
MedicineOncologyPharmacologyBreast OncologyClinical PharmacologyEndocrine PharmacotherapyBreast Cancer PharmacotherapyCancer Survival AnalysisHer2-positive Breast CancerHormonal Cancer TherapyHormonal TherapyMetastatic Breast CancerBreast Cancer Endocrine TherapyBreast Cancer Hormonal TherapyCombination Endocrine TherapyHer2-positive Breast Cancer TherapyHormone Receptor-positive Breast Cancer TherapyHuman Epidermal Growth Factor Receptor 2-Targeted TherapyInterim AnalysisMulticenter Trials
BACKGROUND: A recent large real-world study conducted in the United States reported the effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- advanced breast cancer (ABC). However, local clinical practice and available medical treatment can vary between Japan and Western countries. Thus, it is important to investigate Japanese real-world data. This observational, multicenter study (NCT05399329) reports the interim analysis of effectiveness of palbociclib plus ET as first-line or second-line treatment for HR+/HER2- ABC by estimating real-world progression-free survival (rwPFS) and overall survival (OS) in Japanese routine clinical practice. METHODS: Real-world clinical outcomes and treatment patterns of palbociclib plus ET were captured using a medical record review of patients diagnosed with HR+/HER2- ABC who had received palbociclib plus ET in the first-line or second-line treatment across 20 sites in Japan. The primary endpoint was rwPFS; secondary endpoints were OS, real-world overall response rate, real-world clinical benefit rate, and chemotherapy-free survival. RESULTS: Of the 677 eligible patients, 420 and 257 patients, respectively, had received palbociclib with ET as first-line and second-line treatments. Median rwPFS (95% confidence interval) was 24.5 months (19.9-29.4) for first-line and 14.5 months (10.2-19.0) for second-line treatment groups. Median OS was not reached in the first-line group and was 46.7 months (38.8-not estimated) for the second-line group. The 36-month OS rates for de novo metastasis, treatment-free interval (TFI) ≥ 12 months, and TFI < 12 months were 80.2% (69.1-87.7), 82.0% (70.7-89.3), and 66.0% (57.9-72.9), respectively. CONCLUSION: The addition of palbociclib to ET was effective for treating HR+/HER2- ABC in Japanese routine clinical practice.
29
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.9K citations
Medicine, Oncology, Pharmacology +17
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text
Medicine, Oncology, Breast Oncology +11
Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations
Medicine, Oncology, Pharmacology +17
Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations
Medicine, Oncology, Pharmacology +17
George W. Sledge, Masakazu Toi, Patrick Neven et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text
Medicine, Oncology, Pharmacotherapy +17